Metastatic Breast Cancer (ASCO) Basic Listing

Updates in Metastatic Breast Cancer

From the ASCO Annual Meeting

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer

06/20/2024

Erika Hamilton, MD

Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...

Erika Hamilton, MD discusses the...

06/20/2024

Oncology

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan Remains Superior to Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer

06/07/2024

Allison Casey ;

According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.

According to updated survival...

06/07/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer

06/06/2024

Allison Casey ;

According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.

According to first results from...

06/06/2024

Oncology

Conference Coverage

Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/06/2024

Allison Casey ;

According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.

According to results from a...

06/06/2024

Oncology

Conference Coverage

Antibody Drug Conjugates for Patients With Metastatic Breast Cancer

06/02/2024

Jane Meisel, MD

Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.

Jane Meisel, MD, discusses the...

06/02/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan With or Without Pertuzumab Shows Promise For Previously Untreated Patients With HER2-Positive Metastatic Breast Cancer

05/28/2024

Allison Casey ;

According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known...

According to a phase 1b/2 trial,...

05/28/2024

Oncology

Yutaka Yamamoto, Kumamoto University Hospital

Videos

Pertuzumab Retreatment Improves OS in HER2-Positive Locally Advanced or Metastatic Breast Cancer

06/08/2023

Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.

Yutaka Yamamoto, MD, discusses...

06/08/2023

Oncology

Q&A

Safety and Efficacy of Trastuzumab Deruxtecan for Older Patients with HER2-Positive Metastatic Breast Cancer

06/08/2023

At the 2023 ASCO Annual Meeting, Ian Krop, MD, PhD, discusses the results from an age-specific pooled analysis which evaluated the efficacy and safety of trastuzumab deruxtecan among older patients with HER2-positive metastatic breast cancer.

At the 2023 ASCO Annual Meeting,...

06/08/2023

Oncology

Videos

HER3-DXd for Metastatic Breast Cancer Across Subtypes

06/05/2023

At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.

At the 2023 ASCO Annual Meeting,...

06/05/2023

Oncology

Metastatic Breast Cancer (ASCO) Basic Listing

Specialties

Events

Year Round Education

HMP Global Products